Introduction
The US Food and Drug Administration (FDA) has approved labeling changes for Crestor (rosuvastatin) based on postmarketing studies in Asian-Americans that highlight important information on the safe use of rosuvastatin to reduce the risk for serious muscle toxicity (myopathy/rhabdomyolysis), especially at the highest approved dose of 40 mg.
The FDA has granted approval of a new indication for Temodar (temozolomide) to be used concurrently with radiotherapy and as maintenance therapy after radiotherapy. Temozolomide can extend the lives of adult patients newly diagnosed with glioblastoma multiforme, the most common form of malignant brain cancer.
Antidiabetic Agents
Symlin (pramlintide) Injection
Antihypertensive Agents
Atacand (candesartan cilexetil) Tablets
Antilipemic Agents
Crestor (rosuvastatin) Tablets
Antineoplastic Agents
Temodar (temozolomide) Capsules
Antiviral Agents
Copegus (ribavirin) Tablets
Immunosuppressive Agents
Rapamune (sirolimus) Oral Solution and Tablets
Medscape Pharmacists. 2005;6(1) © 2005 Medscape
Cite this: April 2005 - Medscape - Apr 08, 2005.
